Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.
See the rest here:
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress